



Bone marrow transplant for children with hyper IgM disorder

Clinical Policy ID: CCP.1226

Recent review date: 3/2023

Next review date: 7/2024

Policy contains: Bone marrow transplant; CD40 mutation, CD40 ligand mutation; hematopoietic stem cell transplantation; hyper IgM; pneumocystis jirovecii pneumonia.

AmeriHealth Caritas has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas' clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS) AmeriHealth Caritas has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas' clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by AmeriHealth Caritas when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas' clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas' clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas will update its clinical policies as necessary. AmeriHealth Caritas' clinical policies are not guarantees of payment.

Coverage policy

Bone marrow transplantation is clinically proven and, therefore, medically necessary for children with hyper Immunoglobulin M (IgM) disorder (Bonilla, 2015; National Organization for Rare Diseases, 2023).

Limitations

All other uses of bone marrow transplantation for children with hyper IgM disorder are not medically necessary.

Alternative covered services

No alternative covered services were identified during the writing of this policy.

Background

The hyper IgM syndrome is a rare, inherited immune deficiency disorder resulting from defects in the CD40 ligand (CD40L)/CD40-signaling pathway that affect T cell communication with B lymphocytes (Dunn, 2020). This results in an inability to switch from the production of antibodies of the IgM type to antibodies of the immunoglobulin G (IgG), immunoglobulin E (IgE), and immunoglobulin A (IgA) types. It manifests clinically as a severe life-threatening infection due to defects in humoral and cell-mediated immunity (e.g., fungal infections, opportunistic infections, or bacterial infections).

The diagnosis of hyper IgM syndrome is suggested by flow cytometry showing normal T-cell numbers in the presence of serum IgM that is elevated (or even normal) with reductions in serum IgG, IgE, and IgA (Dunn, 2020). Diagnosis is confirmed with genetic studies, which show mutation in either CD40 or CD40L. A marked reduction in class-switched memory B cells is also present, as are antigen-specific responses (de la Morena, 2017; Dunn, 2020).

About 70% of persons with X-linked hyper IgM disorder inherit the condition in an X-linked recessive pattern, and most cases affect approximately two in 1,000,000 newborn males (National Organization of Rare Diseases, 2018). Autosomal recessive forms of hyper IgM syndrome, known as hyper IgM syndromes type 2, 3, 4, and 5, are extremely rare and appear to affect men and women equally.

Most patients present initially with an elevated susceptibility to infection. A total of 145 patients, 131 of whom were males (median 12 years) with hyper IgM syndrome who were in the U.S. Immunodeficiency Network patient registry showed 91% with infections, with pulmonary, ear, and sinus infections being the most common; 42% had pneumocystis jirovecii pneumonia (Leven, 2016). Overall survival is 20% by age 25 (de la Morena, 2017).

The long-term outcome of X-linked hyper-IgM syndrome caused by mutations in CD40L is poor. Various treatments have been tried, with varying degrees of success, including (Dunn, 2020; Meng, 2018):

- Administration of therapeutic immunoglobulin, antibiotics for infections, and steroids for neutropenia or severe autoimmune manifestations.
- Gene therapy, which remains in the animal testing stage.
- Activation of CD40 receptor regulated by CD40 agonists, which remains incomplete.
- Hematopoietic stem cell transplantation.

Findings

A study of 176 patients diagnosed with X-linked hyper IgM syndrome from 1964 to 2013 were randomized into those receiving hematopoietic stem cell transplantation ($n = 67$) and those who did not ($n = 109$). After follow-up for an average 8.5 years, the two groups had an insignificant difference in overall survival ($P = .671$), which was more than 80%. However, risk associated with transplantation decreased for diagnosis years 1987 to 1995, and the hazard ratio was significantly less than 1.0 for those diagnosed from 1995 to 1999 (de la Morena, 2017).

An international collaborative study ($n = 130$) of patients with CD40L deficiency tracked patients for five years after hematopoietic stem cell transplantation, and determined overall survival, event-free survival, and disease-free survival to be 78.2%, 58.1%, and 72.3%, respectively. Patients who underwent transplantation beginning in 2000 had better outcomes as did children less than 10 years old at the time of the procedure (Ferrua, 2019).

A Japanese study (Mitsui-Sekinaka, 2015) retrospectively analyzed data from 56 patients with hyper IgM disorder, including 29 patients who received hematopoietic stem cell transplantation. The long-term survival rate was poor in those not undergoing transplantation (survival rate at 40 years of age, 28.2%). The overall survival rate of patients undergoing transplantation was significantly higher ($P = .0231$). Moreover, event-free and

disease-free survival rates were significantly greater in patients five years old or younger at the time of transplantation (n = 14) than in older patients (n = 15). The authors note that persistent infections and severe organ damage were frequently observed in patients older than six years.

Wang (2014) retrospectively analyzed the clinical and molecular features of 20 Chinese patients diagnosed with hyper IgM disorder and followed up in hospitals affiliated to Shanghai Jiao Tong University School of Medicine from 1999 to 2013. The median onset age of these patients was 8.5 months (range: 20 days – 21 months). Half of them had positive family histories, which helped identify them as sufferers from the disease. The most common symptoms were recurrent sinopulmonary infections (90%), neutropenia (70%), oral ulcer (65%), and protracted diarrhea (65%). Six patients received hematopoietic stem cell transplants and four had immune reconstructions and clinical remissions. Eighteen unique mutations in CD40L gene were identified, with 12 novel mutations.

Petrovic (2009) retrospectively analyzed the transplantation outcomes of 31 patients with primary immunodeficiency diseases treated at All Children's Hospital in Tampa, Florida. The primary immune diseases included severe combined immunodeficiency, Wiscott-Aldrich syndrome, X-linked hyper IgM syndrome, and chronic granulomatous disease. The age of the patients at the time of transplantation ranged from 1 month to 19 years, and conditioning regimens varied based on the patients underlying disease. In 23 patients, the graft source was bone marrow, four patients received umbilical cord blood grafts, and four patients received peripheral blood stem cell grafts. Better survival rates were observed in patients transplanted at a younger age and with a history free of infections. The authors concluded that transplantation at an early age before significant infections, autoimmune manifestation, and malignant transformation have occurred is beneficial to survival.

In 2022, we added a statement from the National Organization for Rare Diseases (2018) and a joint guideline from the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology (Bonilla, 2015). Both organizations recommend hematopoietic stem cell transplantation as the only curative treatment for hyper IgM disorder, although they admit experience is limited. In addition, the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology guideline issued a moderate-strength recommendation for hematopoietic stem cell transplantation as prophylaxis for *Pneumocystis jirovecii* pneumonia for all patients with known or suspected CD40 or CD40L deficiency, as this infection occurs in 30% to 40% of patients with defects of CD40 or CD40L (Bonilla, 2015). No policy changes are warranted.

In 2023, we updated the references and found no newly published relevant information to add to the policy. No policy changes are warranted.

References

On January 10, 2023, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were : "CD40 (MeSH)," "CD40 ligand (MeSH)," and "hyper IgM syndrome." We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol.* 2015;136(5):1186-1205 e1181-1178. Doi: 10.1016/j.jaci.2015.04.049.

De la Morena MT, Leonard D, Torgerson TR, et al. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. *J Allergy Clin Immunol.* 2017;139(4):1282-1292. Doi:10.1016/j.jaci.2016.07.039.

- Dunn CP, de la Morena MT, Adam MP. X-linked hyper IgM syndrome. Review. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. <https://www.ncbi.nlm.nih.gov/books/NBK1402/>. Published 2007. Last updated February 20, 2020.
- Ferrua F, Galimberti S, Courteille V, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE_PIDTC study. *J Allergy Clin Immunol*. 2019;143(6):2238-2253. Doi: 10.1016/j.jaci.2018.12.1010.
- Leven EA, Maffucci P, Ochs HD, et al. Hyper IgM syndrome: A report from the USIDNET Registry. *J Clin Immunol*. 2016;36(5):490-501. Doi: 10.1007/s10875-016-0291-4.
- Meng X, Yang B, Suen WC. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. *Innate Immun*. 2018;24(1):4-10. Doi: 10.1177/1753425917739681.
- Mitsui-Sekinaka K, Imai K, Sato H, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. *J Allergy Clin Immunol*. 2015 Oct;136(4):1018-1024. Doi: 10.1016/j.jaci.2015.02.020.
- National Organization for Rare Diseases. Rare disease database: Hyper IgM syndromes. <https://rarediseases.org/rare-diseases/hyper-igm-syndrome/>. Published 2023.
- Petrovic A, Dorsey M, Miotke J, Shepherd C, Day N. Hematopoietic stem cell transplantation for pediatric patients with primary immunodeficiency diseases at All Children's Hospital/University of South Florida. *Immunol Res*. 2009;44(1-3):169-178. Doi: 10.1007/s12026-009-8111-z.
- Wang LL, Zhou W, Zhao W, et al. Clinical features and genetic analysis of 20 Chinese patients with X-linked hyper-IgM syndrome. *J Immunol Res*. 2014:683160. Doi: 10.1155/2014/683160.

Policy updates

- 4/2016: initial review date and clinical policy effective date: 7/2016
- 1/2018: Policy references updated.
- 1/2019: Policy references updated. The policy ID changed from 17.02.01 to CCP.1226.
- 12/2019: Policy references updated.
- 3/2021: Policy references updated.
- 3/2022: Policy references updated.
- 3/2023: Policy references updated.